ArticleHuman vaccines & immunotherapeutics2026
Artificial intelligence in immune checkpoint inhibitor research: A bibliometric analysis of the landscape.
Article in Human vaccines & immunotherapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This bibliometric analysis examines the transformative role of artificial intelligence (AI) in immune checkpoint inhibitor (ICI) research. Using VOSviewer, CiteSpace, and Bibliometrix, we analyzed 1,938 publications from the Web of Science Core Collection (2015-2026), revealing a dramatic rise in AI-related ICI studies, led by China and the USA. Key findings demonstrate AI's integration in predicting treatment response, optimizing dosing strategies, and managing immune-related adverse events. Through keyword co-occurrence and citation analyses, we identify critical AI applications including digital pathology and tumor microenvironment characterization. This comprehensive overview provides valuable insights into research trends and emerging frontiers for AI-driven innovations in cancer immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.